Eplerenone potentiates protective effects of amlodipine against cardiovascular injury in salt-sensitive hypertensive rats

Hypertension Research

Volumn 34, Issue 7, 2011, Pages 817-824

  Nakamura, Taishi ^a   Fukuda, Masaya ^a   Kataoka, Keiichiro ^a   Nako, Hisato ^a   Tokutomi, Yoshiko ^a   Dong, Yi Fei ^a   Yamamoto, Eiichiro ^b   Yasuda, Osamu ^b   Ogawa, Hisao ^a   Kim Mitsuyama, Shokei ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

cardiac remodeling; combination therapy; endothelial function; eNOS; oxidative stress

Indexed keywords

AMLODIPINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPLERENONE; PROTEIN KINASE B; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR DISEASE; CARDITIS; COMPARATIVE STUDY; CONTROLLED STUDY; DAHL SALT SENSITIVE RAT; DRUG MECHANISM; DRUG POTENTIATION; ENDOTHELIAL DYSFUNCTION; HEART MUSCLE FIBROSIS; HYPERTENSION; NONHUMAN; RAT; VASCULAR ENDOTHELIUM;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; AMLODIPINE; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CAROTID ARTERIES; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; HEART; HYPERTENSION; MALE; MYOCARDIUM; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, INBRED DAHL; RECEPTOR, ANGIOTENSIN, TYPE 1; SODIUM CHLORIDE, DIETARY; SPIRONOLACTONE; SUPEROXIDES; TREATMENT OUTCOME;

EID: 79959330833     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2011.35     Document Type: Article

References (33)

1. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 1990; 67: 1355-1364.
2. Brown NJ. Aldosterone and vascular inflammation. Hypertension 2008; 51: 161-167. (Pubitemid 351159920)
3. Funder J. Mineralocorticoids and cardiac fibrosis: the decade in review. Clin Exp Pharmacol Physiol 2001; 28: 1002-1006. (Pubitemid 34053511)
4. Kobayashi N, Yoshida K, Nakano S, Ohno T, Honda T, Tsubokou Y, Matsuoka H. Cardioprotective mechanisms of eplerenone on cardiac performance and remodeling in failing rat hearts. Hypertension 2006; 47: 671-679. (Pubitemid 43740237)
5. Nagata K, Obata K, Xu J, Ichihara S, Noda A, Kimata H, Kato T, Izawa H, Murohara T, Yokota M. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension 2006; 47: 656-664. (Pubitemid 43740235)
6. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EA, McMahon EG, Delyani JA. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002; 283: H1802-H1810. (Pubitemid 35217013)
7. Schiffrin EL. Effects of aldosterone on the vasculature. Hypertension 2006; 47: 312-318. (Pubitemid 43740260)
8. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol 2002; 161: 1773-1781. (Pubitemid 35265535)
9. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321. (Pubitemid 36384098)
10. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 1999; 341: 709-717. (Pubitemid 29407370)
11. White WB, Duprez D, St Hillaire R, Krause S, Roniker B, Kuse-Hamilton J, Weber MA. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003; 41: 1021-1026. (Pubitemid 36548598)
12. Flack JM, Oparil S, Pratt JH, Roniker B, Garthwaite S, Kleiman JH, Yang Y, Krause SL, Workman D, Saunders E. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 2003; 41: 1148-1155. (Pubitemid 36384902)
13. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the value randomised trial. Lancet 2004; 363: 2022-2031. (Pubitemid 38781102)
14. Liu L, Wang JG, Gong L, Liu G, Staessen JA. Comparison of active treatment and placebo in older chinese patients with isolated systolic hypertension. Systolic hypertension in china (syst-china) collaborative group. J Hypertens 1998; 16: 1823-1829. (Pubitemid 28548522)
15. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, Bulpitt CJ, de Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C, O¢Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The systolic hypertension in europe (syst-eur) trial investigators. Lancet 1997; 350: 757-764. (Pubitemid 27387202)
16. Nakamura T, Yamamoto E, Kataoka K, Yamashita T, Tokutomi Y, Dong YF, Matsuba S, Ogawa H, Kim-Mitsuyama S. Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan. Hypertension 2008; 51: 296-301. (Pubitemid 351159942)
17. Yamamoto E, Kataoka K, Shintaku H, Yamashita T, Tokutomi Y, Dong YF, Matsuba S, Ichijo H, Ogawa H, Kim-Mitsuyama S. Novel mechanism and role of angiotensin ii induced vascular endothelial injury in hypertensive diastolic heart failure. Arterioscler Thromb Vasc Biol 2007; 27: 2569-2575. (Pubitemid 350158907)
18. Yamamoto E, Kataoka K, Yamashita T, Tokutomi Y, Dong YF, Matsuba S, Ogawa H, Kim-Mitsuyama S. Role of xanthine oxidoreductase in the reversal of diastolic heart failure by candesartan in the salt-sensitive hypertensive rat. Hypertension 2007; 50: 657-662. (Pubitemid 47442728)
19. Nakamura T, Kataoka K, Fukuda M, Nako H, Tokutomi Y, Dong YF, Ichijo H, Ogawa H, Kim-Mitsuyama S. Critical role of apoptosis signal-regulating kinase 1 in aldosterone/salt-induced cardiac inflammation and fibrosis. Hypertension 2009; 54: 544-551.
20. Doi R, Masuyama T, Yamamoto K, Doi Y, Mano T, Sakata Y, Ono K, Kuzuya T, Hirota S, Koyama T, Miwa T, Hori M. Development of different phenotypes of hypertensive heart failure: systolic versus diastolic failure in dahl salt-sensitive rats. J Hypertens 2000; 18: 111-120. (Pubitemid 30093716)
21. Kim S, Yoshiyama M, Izumi Y, Kawano H, Kimoto M, Zhan Y, Iwao H. Effects of combination of ace inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure. Circulation 2001; 103: 148-154. (Pubitemid 32050450)
22. Johar S, Cave AC, Narayanapanicker A, Grieve DJ, Shah AM. Aldosterone mediates angiotensin ii-induced interstitial cardiac fibrosis via a nox2-containing nadph oxidase. Faseb J 2006; 20: 1546-1548.
23. Keidar S, Kaplan M, Pavlotzky E, Coleman R, Hayek T, Hamoud S, Aviram M. Aldosterone administration to mice stimulates macrophage nadph oxidase and increases atherosclerosis development: a possible role for angiotensin- converting enzyme and the receptors for angiotensin ii and aldosterone. Circulation 2004; 109: 2213-2220. (Pubitemid 38625399)
24. Di Zhang A, Cat AN, Soukaseum C, Escoubet B, Cherfa A, Messaoudi S, Delcayre C, Samuel JL, Jaisser F. Cross-talk between mineralocorticoid and angiotensin ii signaling for cardiac remodeling. Hypertension 2008; 52: 1060-1067.
25. Lemarie CA, Paradis P, Schiffrin EL. New insights on signaling cascades induced by cross-talk between angiotensin ii and aldosterone. J Mol Med 2008; 86: 673-678.
26. Robert V, Heymes C, Silvestre JS, Sabri A, Swynghedauw B, Delcayre C. Angiotensin at1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. Hypertension 1999; 33: 981-986. (Pubitemid 29186395)
27. Schiffrin EL, Franks DJ, Gutkowska J. Effect of aldosterone on vascular angiotensin ii receptors in the rat. Can J Physiol Pharmacol 1985; 63: 1522-1527. (Pubitemid 16164351)
28. Ullian ME, Schelling JR, Linas SL. Aldosterone enhances angiotensin ii receptor binding and inositol phosphate responses. Hypertension 1992; 20: 67-73.
29. Fujita T. Mineralocorticoid receptors, salt-sensitive hypertension, and metabolic syndrome. Hypertension 2010; 55: 813-818.
30. Shibata S, Nagase M, Yoshida S, Kawarazaki W, Kurihara H, Tanaka H, Miyoshi J, Takai Y, Fujita T. Modification of mineralocorticoid receptor function by rac1 gtpase: implication in proteinuric kidney disease. Nat Med 2008; 14: 1370-1376.
31. Mihailidou AS, Loan Le TY, Mardini M, Funder JW. Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension 2009; 54: 1306-1312.
32. Vidal A, Sun Y, Bhattacharya SK, Ahokas RA, Gerling IC, Weber KT. Calcium paradox of aldosteronism and the role of the parathyroid glands. Am J Physiol Heart Circ Physiol 2006; 290: H286-H294.
33. Zia AA, Kamalov G, Newman KP, McGee JE, Bhattacharya SK, Ahokas RA, Sun Y, Gerling IC, Weber KT. From aldosteronism to oxidative stress: the role of excessive intracellular calcium accumulation. Hypertens Res 2010; 33: 1091-1101.